Nacuity

New clinical site added and early safety signals observed in trial for treatment of ocular disease caused by oxidative stress First cohort is expected to achieve full enrollment by third quarter 2023 FORT WORTH, Texas, July 11, 2023…

FORT WORTH, Texas, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts, and other ocular diseases caused by oxidative…